TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8091765

Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard endotracheal tube
Number of subjects: 86
Study: 3378660

Group type: EXPERIMENTAL
Intervention: Frusemide-amiloride
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cyclopenthiazide-potassium chloride
Number of subjects: 47
Study: 29406853

Group type: EXPERIMENTAL
Intervention: Ticagrelor (60 mg and 90 mg)
Number of subjects: 12558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12558
Study: 28786805

Group type: EXPERIMENTAL
Intervention: Individual counselling sessions (4 sessions at months 0, 2, 4, and 6)
Number of subjects: 298
Study: 25620436

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg twice daily
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Fondaparinux 5 mg once daily
Number of subjects: 198

Group type: COMPARATOR
Intervention: Both enoxaparin and fondaparinux
Number of subjects: 198
Study: 23725919

Group type: EXPERIMENTAL
Intervention: TAK-085 2 g once daily
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: TAK-085 4 g twice daily
Number of subjects: 610

Group type: COMPARATOR
Intervention: EPA-E 1.8 g/day
Number of subjects: 610
Study: 19955822

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study: 18245013

Group type: EXPERIMENTAL
Intervention: Screening for lung cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate treatment for screen‐diagnosed lung cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed treatment for screen‐diagnosed lung cancer
Number of subjects: 0
Study: 16787894

Group type: EXPERIMENTAL
Intervention: Responsivity education/prelinguistic milieu teaching (RE/PMT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 51
Study: 12934464

Group type: EXPERIMENTAL
Intervention: Current methods of OP prevention and treatment
Number of subjects: 0
Study: 10868643

Group type: EXPERIMENTAL
Intervention: Group I (250 mg i.v. methylprednisolone at 1 and 6 hr)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Group II (500 mg i.v. methylprednisolone at 1 hr before initial OKT3)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Group III (Atgam 15 mg/kg on day 0, OKT3 on day 1)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Group II
Number of subjects: 101

Group type: COMPARATOR
Intervention: Group III
Number of subjects: 101
Study: 9195083

Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg once daily for 14 days)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Nystatin (500,000 U four times daily for 14 days)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 167

Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 167
Study: 7808022

Group type: EXPERIMENTAL
Intervention: Retinoids and carotenoids as chemopreventive agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3585412

Group type: EXPERIMENTAL
Intervention: Immunotherapy with OK-432 combined with chemotherapy
Number of subjects: 311

Group type: COMPARATOR
Intervention: Chemotherapy (control group)
Number of subjects: 311
Study: 31906881

Group type: EXPERIMENTAL
Intervention: Experimental group received two 60-90 min group breastfeeding educational sessions based on the breastfeeding self-efficacy theory along with routine care.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Exclusive breastfeeding in both experimental and control groups.
Number of subjects: 130
Study: 29745884

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 4 and 8 mg/kg in combination with methotrexate (MTX)
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 904

Group type: COMPARATOR
Intervention: Methotrexate (MTX) plus placebo
Number of subjects: 904
Study: 26469809

Group type: EXPERIMENTAL
Intervention: Test toothpaste containing 0.6% Cortex Ilicis Rotundae
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control toothpaste without any active ingredient
Number of subjects: 100
Study: 25538197

Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 24129362

Group type: EXPERIMENTAL
Intervention: Passive dehydration (PAS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Active dehydration (ACT)
Number of subjects: 23
Study: 20971512

Group type: EXPERIMENTAL
Intervention: 15 mg escitalopram
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17713346

Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy (2 mg daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Transdermal estrogen therapy (0.05 mg daily)
Number of subjects: 45
Study: 17035408

Group type: COMPARATOR
Intervention: Obesity (BMI >= 30)
Number of subjects: 10258

Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 10258
Study: 12597081

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (2.5 mmol/L)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Euglycemia (4.5 mmol/L)
Number of subjects: 16
Study: 10910840

Group type: EXPERIMENTAL
Intervention: d‐tubocurarine 3 mg followed by succinylcholine 1.5 mg/kg
Number of subjects: 119

Group type: COMPARATOR
Intervention: mivacurium 0.2 mg/kg
Number of subjects: 119
Study: 8659780

Group type: EXPERIMENTAL
Intervention: Lidocaine (1, 3, and 6 mg.min(‐1))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25, 0.75, and 1.5 mg.min(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 9
Study: 1404502

Group type: EXPERIMENTAL
Intervention: Immediate resuscitation (IV fluid resuscitation initiated in the ambulance and emergency center before surgical intervention)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Delayed resuscitation (IV fluid resuscitation delayed until surgical intervention)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Immediate resuscitation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Delayed resuscitation
Number of subjects: 300
Study: 3620276

Group type: EXPERIMENTAL
Intervention: Isoxicam (300 mg day-1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Piroxicam (40 mg day-1 for the first two days and 20 mg day-1 for the remaining days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both isoxicam and piroxicam
Number of subjects: 40
Study: 30040774

Group type: EXPERIMENTAL
Intervention: Unstable surface group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Stable surface group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 27298410

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) + ipilimumab
Number of subjects: 19
Study: 25015174

Group type: EXPERIMENTAL
Intervention: RBP-6000
Number of subjects: 36
Study: 22240725

Group type: EXPERIMENTAL
Intervention: The Biggest Loser (one episode)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nature reality show (one episode)
Number of subjects: 59
Study: 21095267

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 16064

Group type: EXPERIMENTAL
Intervention: Antithrombins
Number of subjects: 16064

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa antagonists
Number of subjects: 16064

Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 16064

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 16064
Study: 18702962

Group type: EXPERIMENTAL
Intervention: Lowest waist-to-height ratio (WHtR <0.45) in men
Number of subjects: 49032

Group type: EXPERIMENTAL
Intervention: Highest waist-to-height ratio (WHtR >=0.69) in men
Number of subjects: 49032

Group type: EXPERIMENTAL
Intervention: Lowest waist-to-height ratio (WHtR <0.42) in women
Number of subjects: 49032

Group type: EXPERIMENTAL
Intervention: Highest waist-to-height ratio (WHtR >=0.68) in women
Number of subjects: 49032
Study: 15897165

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05%
Number of subjects: 151

Group type: COMPARATOR
Intervention: Calcipotriol solution 0.005%
Number of subjects: 151
Study: 12892806

Group type: EXPERIMENTAL
Intervention: BioGlue (BioGlue Surgical Adhesive; CryoLife, Inc)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard repair alone (Control)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: BioGlue
Number of subjects: 151
Study: 10847132

Group type: EXPERIMENTAL
Intervention: Amplicor HCV Monitor test
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Quantiplex HCV RNA 2.0 assay
Number of subjects: 133

Group type: COMPARATOR
Intervention: Monitor test
Number of subjects: 133

Group type: COMPARATOR
Intervention: Quantiplex assay
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both assays
Number of subjects: 133
Study: 7851597

Group type: EXPERIMENTAL
Intervention: Acrobeads test
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sperm Penetration Assay (SPA)
Number of subjects: 125
Study: 1722697

Group type: EXPERIMENTAL
Intervention: CHVmP + VB (cyclophosphamide, hydroxorubicin, VM26, prednisone, vincristine, and bleomycin)
Number of subjects: 141

Group type: COMPARATOR
Intervention: CHVmP (cyclophosphamide, hydroxorubicin, VM26, prednisone)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: CHVmP + VB
Number of subjects: 141

Group type: COMPARATOR
Intervention: CHVmP
Number of subjects: 141
Study: 6795663

Group type: EXPERIMENTAL
Intervention: Naloxone 1.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 31470886

Group type: EXPERIMENTAL
Intervention: Nutrition intervention aimed at enhancing the nutritional quality of meals served to young children, incorporating best practices from the Child and Adult Care Food Program.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Environmental intervention aimed at increasing providers' environmental health literacy and self-efficacy for integrated pest management (IPM).
Number of subjects: 52

Group type: COMPARATOR
Intervention: Matched attention control group receiving the same amount of attention (6 hours) and educational materials.
Number of subjects: 52
Study: 28487444

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab
Number of subjects: 132

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab in estrogen receptor-positive patients
Number of subjects: 132

Group type: COMPARATOR
Intervention: Chemotherapy alone in estrogen receptor-positive patients
Number of subjects: 132
Study: 25869158

Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 0
Study: 23819631

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZM)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: ACE-inhibitor (ramipril)
Number of subjects: 5000
Study: 21078948

Group type: EXPERIMENTAL
Intervention: BMS-488043 (AI) administered as monotherapy for 8 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BMS-488043 (AI)
Number of subjects: 8
Study: 19506159

Group type: EXPERIMENTAL
Intervention: Dose-dense temozolomide (150 mg/m² days 1 to 7 and 15 to 21)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Metronomic temozolomide (50 mg/m² continuous daily)
Number of subjects: 85
Study: 17719618

Group type: EXPERIMENTAL
Intervention: Unilateral caloric vestibular stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15055895

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1% (0.25 mL) subcutaneously
Number of subjects: 301

Group type: COMPARATOR
Intervention: No local anaesthesia
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: 14-G cannula with local anaesthesia
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: 16-G cannula with local anaesthesia
Number of subjects: 301

Group type: COMPARATOR
Intervention: 14-G cannula without local anaesthesia
Number of subjects: 301

Group type: COMPARATOR
Intervention: 16-G cannula without local anaesthesia
Number of subjects: 301
Study: 12218703

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP)
Number of subjects: 8
Study: 9660150

Group type: EXPERIMENTAL
Intervention: Continuous exercise at 35%, 55%, and 75% of peak oxygen uptake for 5 minutes.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intermittent exercise (30s cycling followed by 30s rest) for 3 minutes at the same resistance and cadence.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adjustment of HR for climatic conditions using the equation HR(corr) = HR(meas) x (1.18308 - (0.0083218 x T(db))).
Number of subjects: 20
Study: 8126244

Group type: EXPERIMENTAL
Intervention: Gaseous oxygen irrigations (1 x a week for 8 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nitrogen irrigations (control)
Number of subjects: 14
Study: 2929966

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg by mouth the evening prior to surgery and 150 mg by mouth before the operation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sodium citrate (30 ml shortly before admission to the operating room)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sodium citrate (30 ml via a separate gastric tube after the first pH measurement)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No premedication (22 patients)
Number of subjects: 100
Study: 921869

Group type: EXPERIMENTAL
Intervention: Suxamethonium administration
Number of subjects: 23
Study: 31409158

Group type: EXPERIMENTAL
Intervention: Preoperative serum LDL-C level in female patients
Number of subjects: 431
Study: 30559004

Group type: EXPERIMENTAL
Intervention: Single intravenous (IV) infusion of LCB01-0371 at doses of 200, 400, 800, and 1200 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single oral administration of LCB01-0371 at a dose of 800 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single intravenous (IV) administration of LCB01-0371 at a dose of 400 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Single intravenous (IV) administration of LCB01-0371
Number of subjects: 36
Study: 28499730

Group type: EXPERIMENTAL
Intervention: Combination therapy with silodosin 8 mg per day and dutasteride 0.5 mg per day for 12 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Dutasteride monotherapy after silodosin withdrawal
Number of subjects: 140
Study: 25961616

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 30
Study: 23053688

Group type: EXPERIMENTAL
Intervention: Anbainuo plus MTX
Number of subjects: 396
Study: 21684068

Group type: EXPERIMENTAL
Intervention: Single postoperative intravesical dose of mitomycin C (40 mg in 40 ml saline)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard management on removal of the urinary catheter
Number of subjects: 284
Study: 20012785

Group type: EXPERIMENTAL
Intervention: Levosalbutamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Racemic salbutamol
Number of subjects: 60
Study: 16397284

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.01 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.03 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.1 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.3 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 1 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 12507747

Group type: EXPERIMENTAL
Intervention: Olanzapine 5-20 mg daily
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 11132737

Group type: EXPERIMENTAL
Intervention: Dextrose 3.5% (Dex) with 10 microg sufentanil
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (NS) with 10 microg sufentanil
Number of subjects: 48
Study: 9279217

Group type: EXPERIMENTAL
Intervention: Canola oil dust control (treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional swine room (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control room exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bronchoprovocation tests
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal lavage cytokines
Number of subjects: 20
Study: 8364262

Group type: EXPERIMENTAL
Intervention: MEMS (electronic medication-event monitoring device)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pill counts (control group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (pill counts)
Number of subjects: 47
Study: 2878088

Group type: EXPERIMENTAL
Intervention: Polymyxin B administered intravenously in small doses
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Polymyxin B
Number of subjects: 28
Study: 29548345

Group type: EXPERIMENTAL
Intervention: Volixibat 20 mg, 40 mg, or 80 mg once daily for 12 days
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Volixibat
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 27634451

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular phrenic nerve block with 10 ml ropivacaine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (10 ml saline)
Number of subjects: 76
Study: 24661520

Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 119
Study: 22964540

Group type: EXPERIMENTAL
Intervention: Guided Internet-based psychodynamic treatment (IPDT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavior therapy (ICBT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 81
Study: 19846183

Group type: EXPERIMENTAL
Intervention: Unheated sunflower oil
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Heated sunflower oil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cream (CR)
Number of subjects: 22
Study: 17630091

Group type: EXPERIMENTAL
Intervention: CASTest scenarios
Number of subjects: 2449

Group type: COMPARATOR
Intervention: Course centre
Number of subjects: 2449

Group type: COMPARATOR
Intervention: Professional group
Number of subjects: 2449

Group type: COMPARATOR
Intervention: Candidate order
Number of subjects: 2449
Study: 16267659

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venlafaxine XR (75 mg daily)
Number of subjects: 0
Study: 14728495

Group type: EXPERIMENTAL
Intervention: Intelligent IV infusion pumps with integrated software for decision support (DS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current IV infusion pump systems without intelligent software
Number of subjects: 0
Study: 11209540

Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin
Number of subjects: 279

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 279
Study: 8647965

Group type: EXPERIMENTAL
Intervention: Cimetidine, 25 to 40 mg/kg daily for 3 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cimetidine vs Placebo
Number of subjects: 70
Study: 1524279

Group type: EXPERIMENTAL
Intervention: Tonsillectomy or adenotonsillectomy
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control (non-receipt of surgery)
Number of subjects: 268
Study: 6666220

Group type: EXPERIMENTAL
Intervention: 40 mg sustained release isosorbide dinitrate
Number of subjects: 10

Group type: COMPARATOR
Intervention: 40 mg isosorbide‐5‐mononitrate
Number of subjects: 10
Study: 30717779

Group type: EXPERIMENTAL
Intervention: Social cognitive theory-based physical activity intervention (16 weeks, 1 session per week, 90 min each)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Social cognitive theory-based physical activity intervention
Number of subjects: 272
Study: 29476613

Group type: EXPERIMENTAL
Intervention: Weight loss (5%, 11%, and 16%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weight maintenance
Number of subjects: 40
Study: 27028745

Group type: EXPERIMENTAL
Intervention: Kikyo-To (KKT) 5.0 g mixed with jelly
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (jelly only)
Number of subjects: 2
Study: 24561145

Group type: EXPERIMENTAL
Intervention: Moderate/severe target lesion calcification
Number of subjects: 6855
Study: 22947882

Group type: EXPERIMENTAL
Intervention: DOR intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 20194302

Group type: EXPERIMENTAL
Intervention: Behavioral neurocardiac training (BNT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Active control (autogenic relaxation)
Number of subjects: 65
Study: 17536128

Group type: EXPERIMENTAL
Intervention: Low carbohydrate, high fat diet (LC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: High carbohydrate, low fat diet (HC)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Urinary 8-epi
Number of subjects: 29
Study: 15542567

Group type: EXPERIMENTAL
Intervention: Isometric contraction at 40% of the maximal torque, sustained until endurance.
Number of subjects: 11
Study: 12188391

Group type: EXPERIMENTAL
Intervention: High dose dexamethasone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Megadose methylprednisolone
Number of subjects: 44
Study: 10192666

Group type: EXPERIMENTAL
Intervention: butylcyanoacrylate
Number of subjects: 94

Group type: COMPARATOR
Intervention: octylcyanoacrylate
Number of subjects: 94
Study: 7752655

Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg daily (group I)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg daily (group II)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg daily (group III)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cicletanine (50 mg and 100 mg)
Number of subjects: 18
Study: 1963691

Group type: EXPERIMENTAL
Intervention: Reproterol alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Reproterol combined with neostigmine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 8
Study: 7286055

Group type: EXPERIMENTAL
Intervention: Anhydrous crystalline theophylline 250 mg (rectal administration)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Microcrystalline theophylline 250 mg (oral administration)
Number of subjects: 9